

Jan Storek

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6168733/jan-storek-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80
papers

3,696
citations

33
h-index

60
g-index

82
ext. papers

4,309
ext. citations

3.9
avg. IF

4.66
L-index

#	Paper	IF	Citations
80	Case Report: Chemotherapy-Associated Systemic Sclerosis: Is DNA Damage to Blame?. <i>Frontiers in Medicine</i> , 2022 , 9, 855740	4.9	0
79	Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
78	Efficacy of Allogeneic Hematopoietic Cell Transplantation for Autoimmune Diseases. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 489.e1-489.e9		2
77	A biomarker-guided, prospective, phase 2 trial of pre-emptive graft-versus-host disease therapy using anti-thymocyte globulin. <i>Cytotherapy</i> , 2021 , 23, 1007-1016	4.8	0
76	A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 102990	4	1
75	Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 28, 53.e1-53.e1 ¹		1
74	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2062-2076	2.2	19
73	Hematopoietic cell transplant outcomes after myeloablative conditioning with fludarabine, busulfan, low-dose total body irradiation, and rabbit antithymocyte globulin. <i>Clinical Transplantation</i> , 2020 , 34, e14018	3.8	2
72	High incidence of <i>Pneumocystis jirovecii</i> pneumonia in allogeneic hematopoietic cell transplant recipients in the modern era. <i>Cytotherapy</i> , 2020 , 22, 27-34	4.8	9
71	Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. <i>Blood Advances</i> , 2020 , 4, 5035-5039	7.8	43
70	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 845-854	4.7	46
69	Anti-thymocyte globulin $\bar{\tau}$ activity against acute myeloid leukemia stem cells. <i>Bone Marrow Transplantation</i> , 2019 , 54, 549-559	4.4	3
68	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, e321-e330	4.7	15
67	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019 , 21, e13145	2.7	14
66	High incidence of hematologic malignancy relapse after allogeneic transplantation in patients with low Epstein-Barr virus-specific T-cell counts. <i>Cytotherapy</i> , 2019 , 21, 886-894	4.8	1
65	Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin. <i>Blood Advances</i> , 2019 , 3, 1394-1405	7.8	5
64	More acute lymphoid leukemia than acute myeloid leukemia blasts are killed by rabbit antithymocyte globulin. <i>Cytotherapy</i> , 2019 , 21, 1161-1165	4.8	2

63	Rabbit Antithymocyte Globulin Serum Levels: Factors Impacting the Levels and Clinical Outcomes Impacted by the Levels. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 639-647	4.7	9
62	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , 2018 , 378, 35-47	59.2	266
61	Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder. <i>Cytotherapy</i> , 2018 , 20, 706-714	4.8	14
60	Influence of Chemotherapy on Allergen-Specific IgE. <i>International Archives of Allergy and Immunology</i> , 2018 , 177, 145-152	3.7	3
59	Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation. <i>Clinical Transplantation</i> , 2018 , 32, e13150	3.8	16
58	Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1961-1964	4.7	38
57	Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning. <i>Transplant Infectious Disease</i> , 2017 , 19, e12677	2.7	5
56	Autologous hematopoietic cell transplantation for systemic sclerosis - a challenge for the Canadian health care system. <i>Cmaj</i> , 2017 , 189, E623-E624	3.5	
55	Anti-thymocyte globulin dosing-per kg or per lymphocyte?. <i>Lancet Haematology,the</i> , 2017 , 4, e154-e155	14.6	2
54	MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells. <i>Immunology and Cell Biology</i> , 2017 , 95, 611-619	5	43
53	Improved survival after acute graft--host disease diagnosis in the modern era. <i>Haematologica</i> , 2017 , 102, 958-966	6.6	50
52	Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination. <i>Blood Advances</i> , 2016 , 1, 152-159	7.8	12
51	Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1654-1663	4.7	28
50	Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. <i>PLoS ONE</i> , 2016 , 11, e0158242	3.7	13
49	Low Counts of B Cells, Natural Killer Cells, Monocytes, Dendritic Cells, Basophils, and Eosinophils are Associated with Postengraftment Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 37-46	4.7	13
48	Antithymocyte Globulin at Clinically Relevant Concentrations Kills Leukemic Blasts. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 815-24	4.7	18
47	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1636-1645	4.7	56
46	Rabbit anti-T cell globulin in allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 959-70	4.7	75

45	Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 385-6	4.7	5
44	Immune cell subset counts associated with graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 450-62	4.7	38
43	High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1156-62	4.7	18
42	Donor-Recipient Matching For Killer Immunoglobulin-Like Receptor Genotypes Confers Protection Against Graft Versus Host Disease Without Affecting Disease Relapse After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2013 , 122, 4628-4628	2.2	
41	Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. <i>Cytotherapy</i> , 2012 , 14, 1258-75	4.8	105
40	Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1471-8	4.7	47
39	Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E. <i>Allergy, Asthma and Clinical Immunology</i> , 2012 , 8, 1	3.2	31
38	Immune reconstitution after hematopoietic cell transplantation. <i>Current Opinion in Hematology</i> , 2012 , 19, 324-35	3.3	149
37	Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 574-85	4.7	39
36	Allergen-specific T cell quantity in blood is higher in allergic compared to nonallergic individuals. <i>Allergy, Asthma and Clinical Immunology</i> , 2011 , 7, 6	3.2	3
35	Immune Reconstitution After Antithymocyte Globulin (ATG)-Conditioned Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2011 , 118, 1981-1981	2.2	3
34	Neuroinflammation and demyelination in multiple sclerosis after allogeneic hematopoietic stem cell transplantation. <i>Archives of Neurology</i> , 2010 , 67, 716-22		30
33	The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 509-14	4.7	50
32	High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 915-26	4.7	53
31	High IL-15 Serum Levels on Day 7 After Hematopoietic Cell Transplantation Are Associated with a Low Likelihood of Graft-Vs-Host Disease and a High Likelihood of Infections. <i>Blood</i> , 2010 , 116, 1271-1271 ²		0
30	GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2010 , 116, LBA-3-LBA-3	2.2	8
29	Recovery of Functional EBV Specific T Cells Is Not Impaired In Patients with Chronic Gvhd.. <i>Blood</i> , 2010 , 116, 1286-1286	2.2	
28	Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. <i>Archives of Neurology</i> , 2009 , 66, 116-20		22

27	FluBup-ATG-TBI for High-Risk or Advanced Adult ALL in Remission: A Retrospective Review of a Mature Cohort.. <i>Blood</i> , 2009 , 114, 3384-3384	2.2	
26	Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 1373-9	4.7	11
25	Immunological reconstitution after hematopoietic cell transplantation - its relation to the contents of the graft. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 583-97	5.4	38
24	Reconstitution of the immune system after hematopoietic stem cell transplantation in humans. <i>Seminars in Immunopathology</i> , 2008 , 30, 425-37	12	166
23	Immune reconstitution following hematopoietic stem-cell transplantation. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 329-48	4.2	57
22	Normal interleukin-7 (IL7) levels and normal IL7 response to CD4 T lymphopenia in patients with multiple sclerosis and systemic sclerosis. <i>Clinical Immunology</i> , 2006 , 121, 118-9	9	1
21	High Busulfan Exposure Is Associated with Worse Outcome in a Daily IV Busulfan and Fludarabine Transplant Regimen.. <i>Blood</i> , 2006 , 108, 313-313	2.2	2
20	Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.. <i>Blood</i> , 2006 , 108, 3148-3148	2.2	
19	Once Daily IV Busulfan Given with Fludarabine in Allogeneic Stem Cell Transplantation Conditioning: High vs Low Busulfan AUC Does Not Alter Toxicities or Transplant Outcome.. <i>Blood</i> , 2005 , 106, 1763-1763	2.2	
18	Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). <i>Clinical Immunology</i> , 2004 , 113, 285-98	9	48
17	Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2003 , 101, 3319-24	2.2	49
16	High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. <i>Blood</i> , 2003 , 102, 2364-72	2.2	192
15	Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Experimental Hematology</i> , 2003 , 31, 941-52	3.1	87
14	Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 781-4.7	4.7	19
13	Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. <i>Transplantation</i> , 2002 , 73, 1154-8	1.8	78
12	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002 , 100, 1602-1610	2.2	149
11	High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. <i>Blood</i> , 2002 , 100, 1602-10	2.2	45
10	Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. <i>Blood</i> , 2001 , 97, 3380-9	2.2	312

9	CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. <i>Blood</i> , 2001 , 98, 3221-7	2.2	208
8	Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. <i>Blood</i> , 2001 , 98, 3505-12	2.2	107
7	Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2001 , 98, 489-91	2.2	107
6	Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. <i>Blood</i> , 2000 , 96, 3290-3293	2.2	74
5	Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation. <i>Transplant Immunology</i> , 1999 , 7, 123-5	1.7	4
4	Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow. <i>Blood</i> , 1997 , 89, 3891-3892	2.2	43
3	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997 , 90, 4705-4709	2.2	288
2	Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts. <i>American Journal of Hematology</i> , 1997 , 54, 131-8	7.1	179
1	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997 , 90, 4705-4709	2.2	7